Citable filing context

IDXX filing events and research context

Server-rendered

IDXX's research view summarizes recent SEC filing context, starting with mda_quarterly from May 5, 2026.

IDXX filing events and research context
FiledItemContext
May 5, 2026mda_quarterlyIDEXX reported total revenue of $1.14 billion for the first quarter of 2026, an increase from $998.4 million in the prior-year period. Growth was primarily driven by the Companion Animal Group (CAG), which generated $1.05 billion in revenue, led by IDEXX VetLab consumables ($412.6 million) and reference laboratory diagnostic services ($386.2 million). Net income rose to $278.4 million, resulting in diluted earnings per share of $3.47. The United States remains the primary market ($725.2 million), with significant contributions from Europe, the Middle East, and Africa ($257.1 million). The company continues aggressive capital allocation toward share repurchases, spending $371.4 million during the quarter. Strategic expansion included the $15.6 million acquisition of a U.S. reference laboratory's customer relationships in September 2025. Financial risks include exposure to geopolitical instability and hostilities in the Middle East, which may disrupt supply chains and increase operating costs in the Asia Pacific and European regions. To mitigate volatility, IDEXX employs foreign currency exchange contracts and interest rate swaps, including a hedge on a $250 million term loan effectively fixed at 3.4% plus a credit spread.
Feb 20, 2026businessIDEXX Laboratories operates through three primary segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD). The company’s financial performance is driven heavily by CAG, which accounts for the vast majority of revenue, specifically through recurring diagnostic sales such as IDEXX VetLab consumables, reference laboratory services, and veterinary software. Growth in this segment is supported by a high installed base of premium instruments, including the new IDEXX inVue Dx Analyzer, and strong customer retention. Financially, IDEXX maintains a robust balance sheet with a conservative leverage profile, reporting a gross debt-to-Adjusted EBITDA ratio of 0.54 as of year-end 2025. The company utilizes a $1.25 billion credit facility to manage liquidity and fund capital allocation, which includes consistent share repurchases intended to offset dilution and return value to shareholders. While the company faces macroeconomic and sector-specific headwinds, it maintains strong operating margins, benefiting from operational productivity and pricing power. Key risks include foreign currency volatility—mitigated through a systematic hedging program—and potential inflationary pressures on labor and product costs. Management remains focused on R&D investment to drive new product development and service expansion, ensuring long-term growth across its global diagnostic and software markets.
Feb 20, 2026mdaIDEXX Laboratories operates through three primary segments, with the Companion Animal Group (CAG) serving as the core driver of revenue and growth. The company focuses on diagnostic and information management solutions for the veterinary industry, leveraging a recurring revenue model supported by high-margin laboratory services and diagnostic equipment. The Water segment provides specialized testing products, while the Livestock, Poultry and Dairy (LPD) segment addresses diagnostic needs for food animal health and milk quality safety. Financial performance is heavily influenced by global trends in pet ownership, the increasing medicalization of companion animal care, and the ongoing integration of digital diagnostic platforms. Key operational risks include maintaining the installed base of diagnostic instruments, navigating competitive pressures in the veterinary diagnostics market, and managing the complexities of global supply chains for specialized testing reagents. The company’s capital allocation strategy prioritizes internal investment in research and development to sustain innovation in point-of-care and reference laboratory technologies. Analysts should monitor the CAG segment’s organic growth rates and the adoption of proprietary software and diagnostic platforms, as these remain the primary indicators of long-term margin expansion and market penetration within the veterinary healthcare ecosystem.

Source: SEC EDGAR filing text and events; period May 5, 2026; filed May 5, 2026.

Continue research

Keep researching IDXX

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →